Abstract
Total number of 252 cycles of GM-CSF-Leucomax Sandoz (5 mg/kg/day s.c.) and/or G-CSF Filgrastim Hoffmann-La Roche (5-10 mg/kg/day s.c.) was applied in 124 children aged from 0.5-20 years during neutropenia associated with chemotherapy of non-Hodgkin's lymphoma (NHL). Twenty four children with NHL treated according to the same chemotherapy protocol but without G-CSF and GM-CSF served as a control group. Our study have demonstrated the good efficacy of both G-CSF and GM-CSF therapy. They shortened the period of neutropenia, reduced the number of febrile days, infection's duration and decreased the frequency of infectious complications.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Immunologic / therapeutic use*
-
Adolescent
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Child
-
Child, Preschool
-
Female
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Infant
-
Infections / complications*
-
Infections / drug therapy*
-
Lymphoma, Non-Hodgkin / complications*
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Male
-
Neutropenia / complications*
-
Poland
-
Survival Rate
Substances
-
Adjuvants, Immunologic
-
Antineoplastic Agents
-
Granulocyte Colony-Stimulating Factor
-
Granulocyte-Macrophage Colony-Stimulating Factor